Clinical Trials
129 trialsIsa-Pom-Dex in Elderly/Frail Subjects With RRMM
UNC Lineberger Comprehensive Cancer Center
DREAMM 14
GlaxoSmithKline
EMBRACE
Ontario Clinical Oncology Group (OCOG)
A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies
Thomas Jefferson University
CLOVER-WaM
Cellectar Biosciences, Inc.
ELISA in Relapsed/Refractory MM
Massachusetts General Hospital
LCI-HEM-MYE-CRD-002: Carfilzomib-Revlimid-Dexamethasone-Elotuzumab in Relapsed/Refractory Multiple Myeloma
Wake Forest University Health Sciences
KarMMa-2
Celgene
SELVEDge
University of Miami
MagnetisMM-9
Pfizer
QUINTESSENTIAL
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma
Massachusetts General Hospital
Mezi-KD
Assistance Publique - Hôpitaux de Paris
ISABELA
Massachusetts General Hospital
A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
Shandong New Time Pharmaceutical Co., LTD
Subcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in Early Relapse
Icahn School of Medicine at Mount Sinai
MUKEight
University of Leeds
PCD
Institut Curie
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Massachusetts General Hospital
Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma
Qilu Pharmaceutical Co., Ltd.
SELECT
Amgen
Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)
AbbVie
Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders
City of Hope Medical Center
KarMMa
Celgene
RAPA-201 T Cell Therapy for Relapsed, Refractory Multiple Myeloma
Rapa Therapeutics LLC
Study of HBI0101 (NXC-201) CAR-T Therapy in Multiple Myeloma and Light-Chain Amyloidosis
Hadassah Medical Organization
TALIM
Gruppo Italiano Malattie EMatologiche dell'Adulto
IFM2014-01
Intergroupe Francophone du Myelome
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
SWOG Cancer Research Network
MUKseven
University of Leeds
A Study of Low Dose Lenalidomide and Dexamethasone in Relapsed/Refractory Myeloma in Patients at High Risk for Myelosuppression
Peter MacCallum Cancer Centre, Australia
Chimeric Antigen Receptor Modified T Cells Targeting BCMA for the Treatment of Relapsed/Refractory Multiple Myeloma
The First Affiliated Hospital of Xiamen University
PANORAMA_3
pharmaand GmbH
DARE
Hellenic Society of Hematology
MUKtwelve
University of Leeds
Maintenance Therapy With Subcutaneous Bortezomib
European Myeloma Network B.V.
GMMG-BIRMA
University of Heidelberg Medical Center
Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib
Oncotherapeutics
A Study of AT9283 in Patients With Relapsed or Refractory Multiple Myeloma
Canadian Cancer Trials Group
MARCH
Antengene Corporation
FUSIONMM-003
Celgene
Human BCMA Targeted T Cells Injection(BCMA CAR-T)for Subjects With R/R MM
Hrain Biotechnology Co., Ltd.
A Phase II Study of Bevacizumab and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma
Hackensack Meridian Health
ESdRRMM
Tulane University
A Study of an Accelerated Infusion Rate of Daratumumab in Patients With Relapsed and Refractory Multiple Myeloma
Canadian Myeloma Research Group
A Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma
AbbVie
UARK 2014-14: Phase II Prospective Evaluation of Bone Remodeling During Ixazomib Treatment
University of Arkansas
Pomalidomide in Gene Expression Profiling (GEP)-Defined High-risk Multiple Myeloma
University of Arkansas
MK-0683-095
Merck Sharp & Dohme LLC
Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer
Fred Hutchinson Cancer Center